First AD

Second AD

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Immunotherapy in Lung Cancer

The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.

Recent Updates in The Role of Immunotherapies in Early NSCLC: Translating Evidence to Clinical Practice

Peer Exchange

Sandip Patel, MD, and Ben Levy, MD, discuss the results and clinical implications of the IMPower-010 and KEYNOTE-091 studies of adjuvant immunotherapy in NSCLC.

Adjuvant Therapy in NSCLC: IMPower-010 and KEYNOTE-091 Studies

Overview of Early-Stage NSCLC and Molecular Testing

Selecting Optimal Treatment in Early-Stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

Perioperative Treatment in Early NSCLC: KEYNOTE-671 and NEOTORCH Studies

Neoadjuvant Versus Perioperative Therapy in Resectable NSCLC

Neoadjuvant Versus Adjuvant Therapy in Resectable NSCLC

Treatment Strategy in Patients with Unresectable Stage I-III NSCLC

Consolidation Immunotherapy in Unresectable Early NSCLC: PACIFIC Study

Consolidation Immunotherapy in Unresectable Early NSCLC: Novel Approaches

Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab

Practice Pearls for Community Oncologists Treating Early-Stage NSCLC